Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Heather Barnett

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|September 19, 2018
Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 InhibitorsPaul Bamborough, Chun-Wa Chung, Rebecca C Furze, et al.
Journal of Medicinal Chemistry|April 24, 2020
Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding ModeSimon C C Lucas, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry|August 1, 2015
Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain InhibitorsPaul Bamborough, Chun-wa Chung, Rebecca C Furze, et al.
Cureus|April 23, 2025
Physicians' Perceptions of Barriers and Facilitators to the Improvement of Healthcare Equity for Children Hospitalized With Traumatic Brain Injury: Preliminary Findings From a Pilot Multicenter Pediatric Trauma Study From the United StatesChelsea D Hicks, Heather Barnett, Jennifer Shi, et al.
Journal of Medicinal Chemistry|January 7, 2020
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment ScreeningChristopher R Wellaway, Dominique Amans, Paul Bamborough, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Medicinal Chemistry|September 19, 2018
Aiming to Miss a Moving Target: Bromo and Extra Terminal Domain (BET) Selectivity in Constrained ATAD2 InhibitorsPaul Bamborough, Chun-Wa Chung, Rebecca C Furze, et al.
Journal of Medicinal Chemistry|April 24, 2020
Optimization of Potent ATAD2 and CECR2 Bromodomain Inhibitors with an Atypical Binding ModeSimon C C Lucas, Stephen J Atkinson, Paul Bamborough, et al.
Journal of Medicinal Chemistry|August 1, 2015
Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain InhibitorsPaul Bamborough, Chun-wa Chung, Rebecca C Furze, et al.
Cureus|April 23, 2025
Physicians' Perceptions of Barriers and Facilitators to the Improvement of Healthcare Equity for Children Hospitalized With Traumatic Brain Injury: Preliminary Findings From a Pilot Multicenter Pediatric Trauma Study From the United StatesChelsea D Hicks, Heather Barnett, Jennifer Shi, et al.
Journal of Medicinal Chemistry|January 7, 2020
Discovery of a Bromodomain and Extraterminal Inhibitor with a Low Predicted Human Dose through Synergistic Use of Encoded Library Technology and Fragment ScreeningChristopher R Wellaway, Dominique Amans, Paul Bamborough, et al.
Pageof 2